Tango Therapeutics Inc (NASDAQ: TNGX)’s stock price has decreased by -6.10 compared to its previous closing price of 1.64. However, the company has seen a -10.72% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2025-03-25 that BOSTON, March 25, 2025 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that five abstracts have been accepted as poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025, in Chicago, Illinois.
Is It Worth Investing in Tango Therapeutics Inc (NASDAQ: TNGX) Right Now?
The 36-month beta value for TNGX is at 0.93. Analysts have varying views on the stock, with 6 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TNGX is 59.12M, and currently, shorts hold a 15.42% of that float. The average trading volume for TNGX on March 27, 2025 was 752.25K shares.
TNGX’s Market Performance
TNGX stock saw a decrease of -10.72% in the past week, with a monthly decline of -33.04% and a quarterly a decrease of -50.32%. The volatility ratio for the week is 8.65%, and the volatility levels for the last 30 days are 10.50% for Tango Therapeutics Inc (TNGX). The simple moving average for the last 20 days is -18.07% for TNGX stock, with a simple moving average of -73.91% for the last 200 days.
Analysts’ Opinion of TNGX
Many brokerage firms have already submitted their reports for TNGX stocks, with Jefferies repeating the rating for TNGX by listing it as a “Buy.” The predicted price for TNGX in the upcoming period, according to Jefferies is $19 based on the research report published on July 17, 2024 of the previous year 2024.
Piper Sandler gave a rating of “Overweight” to TNGX, setting the target price at $18 in the report published on February 12th of the previous year.
TNGX Trading at -36.41% from the 50-Day Moving Average
After a stumble in the market that brought TNGX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -87.18% of loss for the given period.
Volatility was left at 10.50%, however, over the last 30 days, the volatility rate increased by 8.65%, as shares sank -33.91% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -46.15% lower at present.
During the last 5 trading sessions, TNGX fell by -10.72%, which changed the moving average for the period of 200-days by -78.61% in comparison to the 20-day moving average, which settled at $1.8798. In addition, Tango Therapeutics Inc saw -50.16% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TNGX starting from Barry Douglas, who sale 2,774 shares at the price of $2.99 back on Feb 04 ’25. After this action, Barry Douglas now owns 68,570 shares of Tango Therapeutics Inc, valued at $8,289 using the latest closing price.
Barry Douglas, the General Counsel of Tango Therapeutics Inc, sale 2,556 shares at $3.16 during a trade that took place back on Feb 05 ’25, which means that Barry Douglas is holding 66,014 shares at $8,081 based on the most recent closing price.
Stock Fundamentals for TNGX
Current profitability levels for the company are sitting at:
- -3.46 for the present operating margin
- 0.97 for the gross margin
The net margin for Tango Therapeutics Inc stands at -3.1. The total capital return value is set at -0.52. Equity return is now at value -57.58, with -34.96 for asset returns.
Based on Tango Therapeutics Inc (TNGX), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -3.6.
Currently, EBITDA for the company is -145.59 million with net debt to EBITDA at 0.23. When we switch over and look at the enterprise to sales, we see a ratio of 3.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.98.
Conclusion
In conclusion, Tango Therapeutics Inc (TNGX) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
